Home › Drug Codes › J Codes › J3393 · Zynteglo
Updated October 1st, 2026

Zynteglo J Code: J3393

Injection, betibeglogene autotemcel, per treatment

Login to unlock all benchmarks
Medicare Payment Limit ?
Not published
CMS publishes none for Q4 2026
APC Payment Limit ?
$2,925,123.299
/ HCPCS billing unit · APC 0746
ASP ?
No current ASP
Not available for Q4 2026
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
1
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, betibeglogene autotemcel, per treatment
HCPCS Added Date July 1, 2024
Manufacturer Genetix Biotherapeutics
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Form Suspension

About Zynteglo

Zynteglo is a medication aligned to the HCPCS J Code: J3393 for billing, pricing, and reimbursement purposes in the United States. This Genetic Disorder medication is administered via the intravenous route and manufactured by Genetix Biotherapeutics.

Manufacturers, reach out to us to add more information.

NDC Code Information

1 NDC package is crosswalked to J3393. Package detail is available to logged-in subscribers.

Login to view 1 NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

Zynteglo Pricing & Reimbursement

J3393 Private Payer Reimbursement
$7,012.50 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Zynteglo CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Zynteglo Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Transfusion-dependent β-thalassemia

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Zynteglo billing and coding guide?
Billing and coding information for Zynteglo can be found through Bluebird Bio. Visit Here →
Are there any available Zynteglo patient assistance programs?
Zynteglo patient assistance information can be found through Bluebird Bio. Visit Here →
Where can I find Zynteglo prescribing information?
Zynteglo prescribing information can be found at the link below: Visit Here →
Where can I find Zynteglo side effect information?
Information regarding Zynteglo's side effect information can be found at Medline Plus.
Does billing Zynteglo require JZ/JW wastage modifiers?
CMS does not include Zynteglo (J3393) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J3393. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.